Kidney Stones

First Drug for Rapid Stone Expulsion and Pain Relief

OptMed Genitourinary Therapeutics
Kidney stones affect approximately 10 percent of the U.S. population, and about 50 percent of these patients experience stone recurrence. The condition can cause excruciating pain. In 2005, ureteral colic (sharp, spasm-like pain produced when a kidney stone has entered the ureter) was the primary diagnosis for nearly two million physician office visits in the U.S., accounting for more than 600,000 emergency room visits. Current therapy is procedure-based. There are no approved drug treatments.

Preclinical Data

The rationale for diazepam's use in treating kidney stones is based on preclinical studies conducted by OptMed in ex-vivo human ureteral tissue that showed rapid relaxation. OptMed believes that rapid relaxation of the smooth muscle in the ureter could facilitate kidney stone passage, potentially eliminating the need for surgery.
OptMed's kidney stone therapeutic is positioned as a drug that may potentially expel stones rapidly while providing relief from pain through the targeted relaxation of ureteral muscle.